Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports
- 28 October 2015
- journal article
- case report
- Published by Springer Science and Business Media LLC in Osteoporosis International
- Vol. 27 (5), 1923-1925
- https://doi.org/10.1007/s00198-015-3380-y
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension studyOsteoporosis International, 2015
- How long should we treat?Osteoporosis International, 2014
- Global Consensus Statement on Menopausal Hormone TherapyClimacteric, 2013
- Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) TrialJournal of Bone and Mineral Research, 2012
- The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)Journal of Bone and Mineral Research, 2011
- Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone MassJournal of Clinical Endocrinology & Metabolism, 2011
- Fracture risk remains reduced one year after discontinuation of risedronateOsteoporosis International, 2007
- Rapid Loss of Hip Fracture Protection After Estrogen Cessation: Evidence From the National Osteoporosis Risk AssessmentObstetrics & Gynecology, 2004
- Effect of Discontinuation of Estrogen, Calcitriol, and the Combination of Both on Bone Density and Bone MarkersJournal of Clinical Endocrinology & Metabolism, 2002
- Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal womenBone, 2002